Companies
WuXi XDC
ADC-focused CRDMO spun out of WuXi Biologics and WuXi AppTec, covering the whole antibody-drug-conjugate chain from linker-payload synthesis and bioconjugation through GMP fill-finish, with the WuXiDARx conjugation platform and a Singapore dual-sourcing site planned to be operational in 2026.
- Country
- China
- Ticker
- HKEX: 2268
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Production site | GMP manufacturing at Wuxi and Changzhou, China, with a Singapore site planned to be operational in 2026 | wuxixdc.com |
| Capacity | Payload and linker GMP from gram to >10 kg scale at an OEL of 10 ng/m3 (OEB-5); drug-product filling up to 15 million doses per year in 2R vials | wuxixdc.com |
| Capacity | Conjugation production from 5 L to 2,000 L with mAb drug substance integrated in the same building | wuxixdc.com |
| Headcount | About 1,000+ employees worldwide | wuxixdc.com |
| Funding | Listed on the Hong Kong Stock Exchange, stock code 2268 | wuxixdc.com |
| Certification | GMP compliance with FDA, EMA and NMPA regulations | wuxixdc.com |
| Revenue | Revenue and profit growing rapidly as the global ADC CRDMO leader medium confidence | leadingir.com |
Independent sources: leadingir.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| ADC linker chemistry | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.